Ponatinib is a potential therapeutic approach for malignant pleural mesothelioma.

Yang, Yi-Wei; Marrufo, Angelica; Chase, Jillian; Woodard, Gavitt A; Jablons, David M; Lemjabbar-Alaoui, Hassan

Yang, Yi-Wei; Marrufo, Angelica; Chase, Jillian; Woodard, Gavitt A; Jablons, David M; Lemjabbar-Alaoui, Hassan.

Afiliação

Yang YW; Department of Surgery, Thoracic Oncology Program, University of California, San Francisco, San Francisco, California, USA.
Marrufo A; Department of Surgery, Thoracic Oncology Program, University of California, San Francisco, San Francisco, California, USA.
Chase J; Department of Surgery, Thoracic Oncology Program, University of California, San Francisco, San Francisco, California, USA.
Woodard GA; Department of Surgery, Thoracic Oncology Program, University of California, San Francisco, San Francisco, California, USA.
Jablons DM; Department of Surgery, Thoracic Oncology Program, University of California, San Francisco, San Francisco, California, USA.
Lemjabbar-Alaoui H; Department of Surgery, Thoracic Oncology Program, University of California, San Francisco, San Francisco, California, USA.

Exp Lung Res ; 47(1): 9-25, 2021 02.

Article em En | MEDLINE | ID: mdl-33107354

Assuntos

Neoplasias Pulmonares; Mesotelioma Maligno; Mesotelioma; Neoplasias Pleurais; Apoptose; Linhagem Celular Tumoral; Humanos; Imidazóis; Neoplasias Pulmonares/tratamento farmacológico; Mesotelioma/tratamento farmacológico; Neoplasias Pleurais/tratamento farmacológico; Piridazinas

Palavras-chave

DNA damage; cAbl; malignant pleural mesothelioma; ponatinib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pleurais / Mesotelioma Maligno / Neoplasias Pulmonares / Mesotelioma Limite: Humans Idioma: En Revista: Exp Lung Res Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google